Skip to content

A study to evaluate the effect of fenugreek seed in patients with Polycystic ovary syndrome (PCOS).

The mechanisms involved in the action of Furostanolic saponins (Furocyst) in regulating ovarian function in the dehydroepiandrosterone [DHEA] induced polycystic ovary of mouse and its clinical outcomes.

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2020/02/023360
Enrollment
376
Registered
2020-02-14
Start date
Unknown
Completion date
Unknown
Last updated
2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E282- Polycystic ovarian syndrome

Interventions

Intervention1: Furocyst group: furocyst capsules will be given twice a day for 3 months. Furocyst is a saponin extracted from fenugreek seeds(furostanolic saponins). Control Intervention1: Control gro

Sponsors

Chemical Resources CHERESO
Lead Sponsor
Science & Engineering Research Board (SERB), DEPARTMENT OF SCIENCE AND TECHNOLOGY, (DST)
Collaborator

Eligibility

Inclusion criteria

Inclusion criteria: 1 Premenopausal women between 18-45 years of age and BMI less than 42 2 Diagnosed with PCOS by Rotterdam Criteria 3 Adequate hepatic, renal, Cardiac and hematological functions 4 Patients willing to Participate and give informed consent in writing for the study 5 Stable weight for last two months (Change of weight

Exclusion criteria

Exclusion criteria: 1 Post-menopausal women and women with hysterectomy & hyperprolactiinemia 2 Patients with congenital adrenal hyperplasia, Cushingââ?¬•s syndrome 3 Acute or chronic Medical illness including Hepatic, Cardiac or renal insufficiency, COPD, Gastrointestinal Disorders 4 Patients with uncontrol Hypertension, smoking, thyroid dysfunction & Hypo-gonadism 5 Women having oral contraceptives, pregnant or lactating mothers 6 Smoking or drug addicts or with psychiatric illness 7 Patient diagnosed with androgen secreting tumors.

Design outcomes

Primary

MeasureTime frame
The menstrual cycle Follicules growth Change in number of cysts Cysts size Ovarian volume Infertility parameters Timepoint: Baseline Visit 1- 4 th week Visit 2- 8 th week Visit 3- 12 th week

Secondary

MeasureTime frame
Demographic parameters (age BP BMI etc) Clinical parameters (hormonal, biochemical) Reproductive parameters Metabolic parameters lipid profile urea creatinine etc Hirsutism scoring Any Long/ short-term side effect etcTimepoint: Baseline Visit 1 At completion of 1st month of intervention Visit 2 At 2nd month(Mid intervention) Visit 3 At 3rd month (post intervention)

Countries

India

Contacts

Public ContactAparna Shukla

Guide

satyendraks@kgmcindia.edu9415204356

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026